<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>4(7)</volume><submitter>Meadows JJ</submitter><funding>A Heart Like Eva</funding><funding>Kennedy Hammil Pediatric Research Fund</funding><funding>Liam Sexton Foundation</funding><pubmed_abstract>&lt;h4>Background&lt;/h4>In symptomatic neonates with tetralogy of Fallot (sTOF), the initial treatment strategy significantly affects early outcomes, but its long-term impact remains less well defined.&lt;h4>Objectives&lt;/h4>The aim of the study was to compare primary (PR) vs staged repair (SR) in sTOF with respect to reintervention (RI) rates and types, clinical and echocardiographic outcomes, and medication use.&lt;h4>Methods&lt;/h4>Neonates with sTOF undergoing PR or SR and with >1 year of follow-up after complete repair were included. The primary outcome was cumulative RI incidence; secondary outcomes included mortality and late echocardiographic and clinical findings. Propensity scoring adjusted for baseline differences. Landmark analysis assessed RI risk at yearly intervals following complete repair</pubmed_abstract><journal>JACC. Advances</journal><pagination>101919</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12418465</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Clinical Status and Reintervention in Neonates With Symptomatic Tetralogy of Fallot: A Landmark Analysis.</pubmed_title><pmcid>PMC12418465</pmcid><pubmed_authors>Healan SJ</pubmed_authors><pubmed_authors>Pajk AL</pubmed_authors><pubmed_authors>Kamsheh AM</pubmed_authors><pubmed_authors>Dailey-Schwartz A</pubmed_authors><pubmed_authors>Qureshi AM</pubmed_authors><pubmed_authors>Khan HQ</pubmed_authors><pubmed_authors>Chai PJ</pubmed_authors><pubmed_authors>Goldstein BH</pubmed_authors><pubmed_authors>Law MA</pubmed_authors><pubmed_authors>McCracken CE</pubmed_authors><pubmed_authors>Batlivala SP</pubmed_authors><pubmed_authors>Meadows JJ</pubmed_authors><pubmed_authors>Bauser-Heaton H</pubmed_authors><pubmed_authors>Smith JD</pubmed_authors><pubmed_authors>Mascio CE</pubmed_authors><pubmed_authors>Pettus JA</pubmed_authors><pubmed_authors>Nicholson GT</pubmed_authors><pubmed_authors>Maskatia SA</pubmed_authors><pubmed_authors>Asztalos IB</pubmed_authors><pubmed_authors>Glatz AC</pubmed_authors><pubmed_authors>Zhang Y</pubmed_authors><pubmed_authors>Beshish A</pubmed_authors><pubmed_authors>Zampi JD</pubmed_authors><pubmed_authors>Romano JC</pubmed_authors><pubmed_authors>Shahanavaz S</pubmed_authors><pubmed_authors>Petit CJ</pubmed_authors><pubmed_authors>Ligon RA</pubmed_authors></additional><is_claimable>false</is_claimable><name>Clinical Status and Reintervention in Neonates With Symptomatic Tetralogy of Fallot: A Landmark Analysis.</name><description>&lt;h4>Background&lt;/h4>In symptomatic neonates with tetralogy of Fallot (sTOF), the initial treatment strategy significantly affects early outcomes, but its long-term impact remains less well defined.&lt;h4>Objectives&lt;/h4>The aim of the study was to compare primary (PR) vs staged repair (SR) in sTOF with respect to reintervention (RI) rates and types, clinical and echocardiographic outcomes, and medication use.&lt;h4>Methods&lt;/h4>Neonates with sTOF undergoing PR or SR and with >1 year of follow-up after complete repair were included. The primary outcome was cumulative RI incidence; secondary outcomes included mortality and late echocardiographic and clinical findings. Propensity scoring adjusted for baseline differences. Landmark analysis assessed RI risk at yearly intervals following complete repair</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Jul</publication><modification>2026-06-02T17:38:30.119Z</modification><creation>2026-04-18T03:11:16.547Z</creation></dates><accession>S-EPMC12418465</accession><cross_references><pubmed>40713145</pubmed><doi>10.1016/j.jacadv.2025.101919</doi></cross_references></HashMap>